Gujarat Kidney strengthens governance; Reports strong revenue growth in Q2 FY25

Gujarat Kidney And Superspeciality Limited approved key auditor appointments, a postal ballot notice, and ratified Q2 FY25 results, reporting strong consolidated revenue growth of 37.40% despite a decline in standalone profitability.

Board Approves Key Appointments and Corporate Actions

Gujarat Kidney And Superspeciality Limited held its board meeting on March 19, 2026, where it approved several important corporate governance measures. The meeting resulted in the appointment of auditors for the financial year 2025–26, approval of a postal ballot notice, and ratification of earlier financial decisions.

The session, conducted at the company’s registered office, also formalised decisions taken in a previous board meeting held on February 14, 2026.

Auditor Appointments for FY26

The board appointed Dharmendra Bhaliya as Secretarial Auditor for FY26. An Associate member of the Institute of Company Secretaries of India, he brings expertise in corporate laws, including the Companies Act, SEBI regulations, and FEMA.

For the role of Internal Auditor, the company appointed Siddharth Atulbhai Shah, an Associate member of the Institute of Chartered Accountants of India. He has around seven years of experience in internal audit, forensic accounting, and risk management.

Postal Ballot and Compliance Measures

The board also approved a postal ballot notice to seek shareholder approval for specific resolutions. Additionally, it ratified actions taken during the February 14 meeting, addressing a compliance gap related to the SEBI (LODR) Regulations, 2015.

The earlier financial results were resubmitted with corrections to typographical errors, ensuring adherence to regulatory disclosure norms following the company’s listing in December 2025.

Q2 FY25 Financial Performance

The company reported a mixed financial performance for Q2 FY25, with strong revenue growth but pressure on profitability.

Standalone Performance:

Revenue from operations rose 2.47% to ₹964.26 lakh

Total income increased 2.15% to ₹965.77 lakh

Net profit declined 22.18% to ₹230.12 lakh

EPS fell to ₹0.45 from ₹0.65

Consolidated Performance:

Revenue surged 37.40% to ₹1,292.88 lakh

Total income grew 37.69% to ₹1,301.67 lakh

Net profit dipped slightly by 2.74% to ₹287.64 lakh

EPS stood at ₹0.52

The strong consolidated growth reflects contributions from its subsidiary entities and expanded healthcare operations.

Contribution from Subsidiaries

The consolidated performance includes operations from associated healthcare units such as Gujarat Surgical Hospital, Surya Hospital and ICU, and Raj Palmland Hospital Private Limited.

These entities have played a significant role in driving higher revenue, highlighting the benefits of the company’s diversified healthcare portfolio.

Focus on Governance and Growth

The latest board decisions underline the company’s focus on strengthening governance frameworks while maintaining operational growth. By appointing experienced auditors and ensuring regulatory compliance, the company aims to enhance transparency and investor confidence.

At the same time, its steady revenue growth reflects continued demand for healthcare services and the effectiveness of its multi-entity operational model.